Botox (onabotulinumtoxinA) treatment for chronic migraine is one of the highest-revenue procedures in neurology — and one of the most denial-prone. A single 31-injection treatment session can pay $1,200–$2,400 in combined drug and administration reimbursement, and a busy chronic migraine clinic runs 80–150 treatment sessions per quarter. The dollars add up fast, and so do the denials when the billing workflow isn’t built around the unique requirements of J-code billing.
If your practice is struggling with Botox migraine denials or your drug reimbursement looks lower than peers, the problem is almost always one of three things: incomplete prior authorization, J-code unit billing errors, or missing administration code documentation. This guide walks through how AMS Solutions’ AAPC-certified team handles Botox chronic migraine billing — every code, every modifier, every payer touch point — and how to build the front-end workflow that turns this from a denial liability into a reliable revenue stream.
The Codes You’re Billing on Every Botox Migraine Session
A complete Botox chronic migraine claim has three components:
1. The drug (J0585 — onabotulinumtoxinA, billed per unit)
J0585 is the HCPCS code for onabotulinumtoxinA. It’s billed in single-unit increments, with chronic migraine standard protocol calling for 155 units across 31 injection sites (the PREEMPT protocol). The drug reimbursement is the largest component of the total claim — typically $900–$1,800 depending on payer and acquisition cost.
2. The administration (CPT 64615 — chemodenervation of head/neck for chronic migraine)
CPT 64615 (whose work RVU was updated in the 2026 coding cycle) is the bundled code for chemodenervation of muscles innervated by facial, trigeminal, cervical spinal, and accessory nerves for chronic migraine. It includes all the injection sites for the standard PREEMPT protocol — do NOT bill individual injection codes (64612, 64616, etc.) alongside 64615 for the same chronic migraine session.
3. The office visit (when applicable)
A separately identifiable E&M service on the same date as the injection can be billed with modifier -25 on the E&M code. The documentation must support a clearly separate service — re-evaluation of migraine pattern, medication management, neurological exam findings — beyond what’s intrinsic to the injection procedure.
J0585 Unit Billing: The Most Common Error
J0585 is billed per unit of drug. The standard PREEMPT protocol uses 155 units divided across 31 injection sites. Your claim should show:
- Quantity: 155 (assuming standard protocol)
- Code: J0585
Documentation must explicitly state:
- Drug name (onabotulinumtoxinA, brand name Botox)
- Total dose administered (155 units, or actual dose if different)
- Injection sites by anatomic location
- NDC number (required for many payers)
- Lot number (required for some payers)
Common errors:
- Billing 1 unit instead of 155 (massive underpayment)
- Billing 155 units when only 100 were administered (overbilling — audit risk)
- Missing NDC on the claim
- No documented wastage when the vial wasn’t fully used
For partial-vial usage, the JW modifier may be used to bill discarded drug — but only when documentation clearly supports the wastage amount and the payer accepts JW billing.
Prior Authorization: Where Most Botox Claims Die
Nearly every commercial payer and Medicare Advantage plan requires pre-authorization for Botox chronic migraine treatment. The PA criteria are stringent and vary by payer, but the universal requirements include:
- Diagnosis confirmation: Chronic migraine (G43.701, G43.711, G43.719) with 15+ headache days per month, 8+ of which are migraine days, for at least 3 months.
- Failed prior treatments: Documentation of failure of, contraindication to, or intolerance to at least 2 (often 3) preventive medication classes — beta-blockers, anticonvulsants (topiramate, divalproex), tricyclic antidepressants, CGRP antagonists.
- PREEMPT protocol adherence: Treatment plan must follow the 155 units / 31 sites protocol.
- Provider qualifications: Some payers require the provider to be a neurologist or have specific certification.
The PA process typically takes 5–10 business days, and rejections at the PA stage are rarely overturned without significant additional documentation. The single highest-impact workflow change for a chronic migraine clinic is a dedicated PA queue that processes the full clinical packet 7–10 days ahead of every scheduled treatment.
Reimbursement Cycle: First Treatment vs. Maintenance
Most payers approve the first Botox migraine cycle conditional on demonstrated response. After the second treatment cycle (around 12 weeks in), the payer requires documentation of clinical response — typically defined as ≥50% reduction in headache days, or significant reduction in headache severity/disability scores.
Without documented response after cycle 2, payers will deny subsequent treatments. The dictation template for follow-up visits should explicitly track:
- Headache days per month before and after
- Migraine days per month before and after
- MIDAS or HIT-6 disability score before and after
- Medication use reduction (acute and preventive)
Tracking these numbers from the start of treatment prevents the predictable denial that hits between treatments 2 and 3.
Common Denial Patterns
The top five Botox migraine denial categories:
- Pre-auth missing (CO-197). Most preventable, highest dollar value. Build the PA queue.
- Medical necessity for continued treatment (CO-50). Cycle-3+ treatments denied because response data wasn’t documented from cycles 1–2.
- Frequency limits (CO-18). Botox migraine treatments billed at less than 12-week intervals without medical necessity documentation.
- J0585 unit error (CO-N822). Unit count mismatch between billed and documented.
- Bundling on E&M (CO-97). E&M code on same date billed without -25 modifier or without documentation of separate service.
What Strong Botox Migraine Documentation Looks Like
The procedure note for every Botox migraine session should explicitly include:
- Pre-procedure verification of PA on file
- Pre-procedure verification of headache calendar showing ongoing chronic migraine pattern (for cycle 2+)
- Total units administered (155 or actual)
- Anatomic injection sites listed (or PREEMPT protocol referenced)
- NDC and lot number
- Drug wastage amount if any, with disposal documentation
- Patient tolerance and any complications
- Plan for next cycle (typically 12 weeks)
The follow-up visit note should explicitly include:
- Headache calendar review (HA days/month, migraine days/month)
- Disability score (MIDAS or HIT-6)
- Acute medication use frequency
- Response assessment (improved, unchanged, worsened)
- Treatment plan continuation rationale
Standardized templates that prompt for these fields prevent the cycle-3 denial cliff that catches many chronic migraine clinics.
How AMS Solutions Handles Botox Migraine Billing
AMS Solutions has been doing medical billing for neurology since 1992. We submit clean claims within 24 hours of charge entry, and our Bespoke Team model means AAPC-certified, neurology-trained coders work every Botox migraine claim — including managing the PA workflow, drug NDC tracking, and response-documentation queue.
When we onboard a chronic migraine clinic, the first thing we do is a free practice audit that maps every Botox claim in the last six months against documentation, PA records, and payer-policy criteria. The recovered revenue typically pays for the engagement many times over in the first quarter.
Frequently Asked Questions
CPT 64615 — chemodenervation of muscles innervated by facial, trigeminal, cervical spinal, and accessory nerves, for chronic migraine. Do not bill individual injection codes (64612, 64616, etc.) alongside 64615 for the same chronic migraine session.
J0585 is billed per unit. The standard PREEMPT protocol uses 155 units, so the claim should show quantity = 155 with code J0585. Documentation must support the exact unit count administered, with NDC number and lot number included on the claim where required by payer.
Yes — Medicare covers Botox for chronic migraine when criteria are met (chronic migraine diagnosis, 15+ headache days/month, prior preventive medication failure). Medicare does not require pre-auth, but documentation must support medical necessity. Medicare Advantage plans generally do require pre-auth.
Most payers require documented clinical response after cycle 2 — typically ≥50% reduction in headache days, or significant reduction in disability score (MIDAS, HIT-6), to approve cycles 3+. Track these metrics from baseline and document at every follow-up to prevent the cycle-3 denial cliff.
Yes, when a separately identifiable E&M service is performed — re-evaluation of migraine pattern, medication management, distinct neurological exam. Append modifier -25 to the E&M code. The documentation must support a service clearly beyond what’s intrinsic to the injection.
Combined drug (J0585) and administration (64615) reimbursement typically runs $1,200–$2,400 per session, varying by payer and acquisition cost. The drug component is the largest piece — and the most commonly underpaid when unit billing is wrong.
At least 7–10 business days ahead of the scheduled treatment date. PA approval typically takes 5–10 business days and rejected requests require time for resubmission with additional documentation. A dedicated PA queue that initiates at scheduling is the single highest-impact workflow for chronic migraine clinics.
Stop letting Botox migraine denials drain your clinic’s revenue.
AMS Solutions has been doing medical billing for neurology since 1992. Our AAPC-certified, HIPAA-compliant team audits your Botox migraine claims end-to-end — PA workflow, J0585 unit billing, response documentation, and denial trends — and tells you exactly where the revenue is leaking.
Free Download: 2026 Neurology CPT Cheat Sheet
EEG, EMG/NCS, OnabotulinumtoxinA for chronic migraine, and the prior-auth gauntlet codes neurology billing teams need at their fingertips. Save it for your team.
Download the Cheat Sheet